Lynkmont-LC Tablet is a combination pharmaceutical formulation containing Levocetirizine 5 mg and Montelukast 10 mg, indicated for the management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedative antihistamine, selectively antagonizes peripheral H1 receptors, thereby mitigating symptoms including sneezing, nasal congestion, rhinorrhea, and pruritus. Montelukast, a leukotriene receptor antagonist, inhibits the cysteinyl leukotriene receptor, reducing airway inflammation, bronchoconstriction, and mucus secretion associated with allergic asthma and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from both histamine-mediated and leukotriene-mediated allergic responses. Lynkmont-LC is prescribed to improve patient quality of life by alleviating nasal and respiratory symptoms and preventing asthma exacerbations. The recommended dosage should be adhered to as per physician guidance, considering patient-specific factors such as age, severity of symptoms, and comorbidities. Caution is advised in patients with hepatic or renal impairment. Adverse effects are generally mild and may include headache, fatigue, dry mouth, or gastrointestinal discomfort. This combination therapy offers an effective and convenient option for patients requiring dual-action treatment for allergic disorders.